A ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1




*As of 7/2022. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP).

#1 prescribed oral JAK Inhibitor in AD.

*As of 7/2022. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP).

RINVOQ is an oral JAK inhibitor for refractory, moderate to severe AD1

Available in 2 dosage strengths1

  • For adults <65 years and pediatric patients 12+ years weighing at least 40 kg (88 lb), initiate treatment with 15 mg orally once-daily
    • If an adequate response is not achieved, consider increasing the dosage to 30 mg once-daily
    • Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose
    • Use the lowest effective dose needed to maintain response
  • For patients ≥65 years of age, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment, the recommended dose of RINVOQ is 15 mg once-daily


  • RINVOQ tablets should be taken orally with or without food
  • Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ
  • RINVOQ is an extended-release tablet, do not split, crush, or chew. Ensure tablet is swallowed whole

AD=atopic dermatitis.

RINVOQ® (upadacitinib) packaging.
  • Coadministration of RINVOQ with strong CYP3A4 inducers is not recommended
  • RINVOQ initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute neutrophil count (ANC) less than 1,000 cells/mm3, or hemoglobin level less than 8 g/dL
  • RINVOQ is not recommended for use in patients with severe hepatic impairment (Child-Pugh C)
  • RINVOQ treatment should be interrupted if a patient develops a serious infection until the infection is controlled
  • RINVOQ is not recommended for use in patients with end stage renal disease (eGFR <15 mL/min/1.73m2)
  • Interruption of dosing may be needed for management of laboratory abnormalities. See monitoring and treatment considerations


Poll results icon.

Want to learn about rapid skin clearance patients can see? In clinical studies
of RINVOQ, many patients achieved EASI 75 and vIGA 0/1 at Week 16.1

Itching to see more? See what patients experienced with RINVOQ in clinical trials.

Are your patients seeking treatment for the rash of atopic dermatitis?

Is itch a primary concern?

Safety is important to you. Want to know more about the safety profile of RINVOQ?

Want to know more about monitoring guidelines for RINVOQ?

RINVOQ Complete can help patients get the support they need to start
and stay on track with their prescribed treatment.

Familiar with Complete? RINVOQ Complete offers the same exceptional
AbbVie support you know and trust.

Enroll patients in

RINVOQ® Complete logo.
to help them get the support and resources they need
to get started and stay on track with RINVOQ

Need RINVOQ samples or want to request an appointment with a Rep?